Altimmune (ALT) Profit After Tax (2010 - 2026)
Altimmune (ALT) posted quarterly Profit After Tax of -$22.9 million for Q1 2026, down 16.6% year-over-year from -$27.4 million in Q1 2025, and up 16.44% quarter-over-quarter from -$27.4 million in Q4 2025.
Altimmune (ALT) Profit After Tax (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Profit After Tax for 17 consecutive years, with -$22.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 16.6% year-over-year to -$22.9 million; the TTM figure through Mar 2026 stood at -$91.4 million (down 1.26% YoY), while the FY2025 annual figure was -$88.1 million, up 7.3% from the prior year.
- Profit After Tax climbed to -$22.9 million in Q1 2026 per ALT's latest filing, from -$27.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$16.1 million in Q2 2023 and bottomed at -$31.6 million in Q4 2023.
- Historically, Profit After Tax has averaged -$22.3 million across 5 years, with a median of -$22.1 million in 2025.
- Annual changes were most pronounced in 2022 — Profit After Tax increased 29.4% — and 2024, when it slumped 53.42%.
- Altimmune's Profit After Tax stood at -$21.7 million in 2022, then plunged by 46.08% to -$31.6 million in 2023, then climbed by 26.84% to -$23.1 million in 2024, then declined by 18.18% to -$27.4 million in 2025, then increased by 16.44% to -$22.9 million in 2026.
- Business Quant data shows ALT's Profit After Tax at -$22.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -23.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.64 Mn |
| Mar 31, 2026 | -22.86 Mn |
| Dec 31, 2025 | -27.36 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.61 Mn |
| Dec 31, 2024 | -23.15 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -16.06 Mn |
| Mar 31, 2023 | -20.07 Mn |
| Dec 31, 2022 | -21.66 Mn |
| Sep 30, 2022 | -23.66 Mn |
| Jun 30, 2022 | -20.11 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |